ABIVAX加强执行管理团队高层官员

StephenW

ABIVAX Strengthens Executive Management Team With Senior Appointments


PARIS, October 30, 2014 /PRNewswire/ --

Karl Birthistle, M.D., appointed VP of Global Regulatory Affairs

Daniel Kenny appointed Chief Commercial Officer & VP of Business Development

ABIVAX, the Paris-based clinical stage biopharmaceutical company specialised in the development and commercialisation of therapeutic vaccines and anti-viral compounds, today announced the appointments of Karl Birthistle, M.D., and Daniel Kenny to its Executive Management team as VP of Global Regulatory Affairs and Chief Commercial Officer & VP of Business Development, respectively.

ABIVAX is establishing itself as a world leader in specialty vaccine and anti-viral drug development to combat infectious and malignant diseases, by developing a number of innovative therapeutic vaccines and antivirals, including clinical stage products ABX203 therapeutic vaccine against chronic hepatitis B and the antiviral ABX464 against HIV.

These two senior appointments further strengthen the Executive Management team led by Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX and supported by both the Board of Directors and the Company's Scientific Advisory Board.

Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX, said: "ABIVAX is a highly ambitious company that is utilizing novel cutting edge science together with strategic partnerships to develop novel therapeutic vaccines and anti-viral drugs.  This will allow us to reduce the human suffering and economic impact of some of the most important infectious diseases faced by the world today. Karl and Daniel, with whom I have been fortunate to have worked with in the past, are recognised industry leaders in their respective fields, reinforcing the strength of the ABIVAX world-class Executive Team."

Biography of Karl Birthistle M.D., Vice President Global Regulatory Affairs

Karl Birthistle is a physician with broad experience in a number of therapeutic areas, gained as he progressed from a Cardiology Intern in Dublin to Senior Registrar in Virology at George's Hospital Medical School in London. After more than 10 years treating patients, Karl joined the pharmaceutical and biotech industry and held positions of increasing responsibility in drug, biologics and vaccines development and medical affairs. He has previously worked at SmithKlineBeecham (Harlow, UK), Bayer (Slough, UK), Pharming (Leiden) and Baxter BioScience (Vienna, Austria), where he was Therapeutic Area Head for Immunology and Critical Care. He went on to become Director of Clinical Development and Safety Assessments for Philip Morris (Neuchatel, Switzerland), and then joined Swissmedic (Bern, Switzerland), the regulatory authority in Switzerland, as Deputy Head, Division Clinical Review.

Biography of Daniel Kenny, Chief Commercial Officer & VP Business Development

Daniel Kenny is an accomplished biopharmaceutical business leader, with almost 30 years' experience in the Global Pharmaceutical industry. In his career he has developed and successfully driven business with industry leaders such as Roche (strategic marketing plans for the launch of Tamiflu®) and Allergan. Prior to joining ABIVAX, Daniel served as Global Franchise Head at Baxter Vaccines. In this role he led a successful reinvigoration of the base commercial business, significantly exceeding the financial plan for the Franchise in each of the three years of his tenure. Before assuming this post, Daniel served as Vice President Baxter BioScience, EMEA with responsibility for all marketing and key business programmes in support of regional sales exceeding $1.9billion. Daniel completed over 10 years in clinical research in the fields of ophthalmology and HIV/AIDS prior to join the pharmaceutical industry. Daniel is a graduate in Physics from the University of New South Wales and has completed Executive business studies at both INSEAD and the London Business School.

ABIVAX Executive Management team

    Prof. Hartmut J Ehrlich, M.D., Chief Executive Officer
    Karl Birthistle, M.D., Vice President Global Regulatory Affairs
    Alain Chevallier, Chief Financial Officer
    Bernard Fanget, Vice President Process Development and Manufacturing
    Daniel Kenny, Chief Commercial Officer & Vice President Business Development
    Didier Scherrer Ph. D., Vice President R&D Small Molecules
    Vincent Serra Ph. D., Vice President R&D Viral Vaccines
    Pierre Vandepapelière M.D., Ph. D., Chief Medical Officer & Vice President Clinical Development


ABIVAX Board of Directors

    Philippe Pouletty, M.D., Chairman (Managing Partner - Truffle Capital)
    Joy Amundson, Former President of Baxter BioScience, BoD of Covidien
    Claude Bertrand, Executive Vice President R&D of Ipsen
    Jean-Jacques Bertrand, Ex CEO of Aventis-Pasteur, President of Pierre Fabre
    Jérôme Gallot, Former CEO of Veolia Transdev and Veolia Environment
    Antoine Pau, Finance Director at Truffle Capital
    Christian Pierret, Former French Minister of Industry
    Jean-Paul Prieels, Former Senior Vice President R&D at GSK Biologicals
    Miguel Sieler, Former Chairman and CEO Bayer France, CEO of Neovacs


ABIVAX Scientific Advisory Board

    Prof. Luc Teyton, M.D., Ph. D., (Chair) Dept. of Immunology, The Scripps Institute, La Jolla, CA, USA
    Prof. Diane Harper, M.D., Chair, Department of Family and Geriatric Medicine, University of Louisville, KY, USA
    Prof. Christoph Huber, M.D., Former Chair, Hematology-Oncology, University of Mainz, Germany
    Jean-Paul Prieels, Ph.D., Former Vice President R&D at GSK Biologicals, Belgium, BoD ABIVAX
    Prof. Lawrence Stanberry, M.D., Ph. D., Chair, Department of Pediatrics, Columbia University, New York, USA
    Prof. Jamal Tazi, Ph. D., Department of Molecular Genetics, University of Montpellier, France
    Prof. Mark A. Wainberg, M.D., Ph. D., Director McGill University AIDS Centre, Montreal, Canada


About ABIVAX

ABIVAX is a Paris-based clinical stage biopharmaceutical company focused on becoming a global leader in the discovery, development and commercialisation of therapeutic vaccines and anti-viral compounds to treat some of the world's most important infectious diseases.

The ABIVAX development portfolio consists of 2 lead compounds that are in clinical stage research: ABX203, a therapeutic vaccine candidate that could be a cure for chronic hepatitis B and ABX464, a novel small molecule against HIV. The broader ABIVAX portfolio includes additional therapeutic vaccines and anti-viral compounds that may enter the clinical stage in the coming 12-18 months.

ABIVAX utilises a technology platform leveraging RNA-protein interaction Interference, B cell and cytotoxic TH1 cell amplification to generate proprietary breakthrough therapies that are designed to help patients clear important pathogenic viruses such as HIV, HBV and HPV.

ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), the British Columbia Cancer Agency (Vancouver, Canada), the CNRS (Montpellier, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA) and the Institut Pasteur (Paris, France). ABIVAX also intends to pursue business development opportunities to access commercial products for licensing agreements as part of its overall corporate strategy.

For more information, please visit the company's website: http://www.abivax.com

Contacts

ABIVA
Prof. Hartmut J. Ehrlich, CEO

Press Relations
Citigate Dewe Rogerson
Ari Levine - Lucie Larguier (Paris)
David Dible (London)
[email protected] / david. [email protected]
+33-1-53-32-84-71 / +44-20-7282-2949

SOURCE ABIVAX


ABIVAX加强执行管理团队高层官员任命




巴黎，二零一四年十月三十日/新华美通/ -  

卡尔Birthistle，MD，任命全球法规事务副总裁

丹尼尔·肯尼任命为业务发展首席商务官和副总裁

ABIVAX，总部位于巴黎的临床阶段生物制药公司，专业从事开发和治疗性疫苗和抗病毒化合物的商业化，今天宣布卡尔Birthistle，MD，和丹尼尔·肯尼的任命其高级管理团队，全球法规事务的副总裁兼首席商务官和，分别为业务开发副总裁的。

ABIVAX是确立了自己作为一个世界领先的特种疫苗和抗病毒药物的开发，以打击传染病和恶性疾病，通过开发一些创新的治疗性疫苗和抗病毒药物，包括临床阶段产品ABX203对慢性乙型肝炎抗病毒ABX464治疗性疫苗抗HIV。

这两个高层官员的任命进一步加强领导的教授哈特穆特·埃利希，MD，ABIVAX的首席执行官和董事均董事会和公司的科学顾问委员会支持的高层管理团队。

教授哈特穆特·埃利希，MD，ABIVAX的首席执行官说：“ABIVAX是采用新型的前沿科学与战略合作伙伴关系，以开发新的治疗性疫苗和抗病毒药一个雄心勃勃的公司这将使我们能够减少人力。痛苦与一些面临的当今世界，卡尔和Daniel，最重要的传染病人，我很幸运，在过去工作过，都是在各自领域公认的行业领导者的经济影响，增强的实力ABIVAX世界级的管理团队。“

卡尔Birthistle医学博士，副总裁兼全球法规事务的简历

卡尔Birthistle是在许多治疗领域有着丰富的经验，取得了他从实习生心脏病在都柏林为高级处长病毒学进展，在乔治医院医学院在伦敦医生。经过十多年的治疗患者，卡尔加入了制药和生物技术行业，并举行了越来越多的药物，生物制剂和疫苗的开发和医疗事务负责职务。他曾供职于SmithKlineBeecham（哈洛，英国），拜耳（斯劳，英国），网址嫁接（莱顿）和百特生物科学公司（奥地利维也纳），在那里他治疗领域负责人免疫学与危重监护。他后来成为临床开发部主任和安全评估为菲利普莫里斯（纳沙泰尔，瑞士），然后加入瑞士医药管理局（瑞士伯尔尼），瑞士的监管机构，为副团长，师临床复查。

传丹尼尔·肯尼，首席商务官兼业务开发副总裁

丹尼尔·肯尼是一个多才多艺的生物制药企业的领导者，在全球制药业近30年的经验。在他的职业生涯，他已开发并成功驱动，行业领袖企业，如罗氏公司（战略营销计划的推出达菲）和眼力。在加入ABIVAX，丹尼尔曾担任百特疫苗全球连锁加盟负责人。在这个职位上，他领导的基地商用业务的成功复兴，显著高于在三个年度各年他的任期的特许经营的财务计划。在担任这一职位，丹尼尔担任副总裁百特生物科学，EMEA与支持地区销售超过$1.9billion的所有市场营销和关键业务计划的责任。丹尼尔完成了超过10年的临床研究，眼科和艾滋病毒/艾滋病投身医药行业之前的领域。丹尼尔是物理学毕业于新南威尔士大学，并在两个欧洲工商管理学院和伦敦商学院完成行政商务研究。

ABIVAX执行管理团队

    教授哈特穆特Ĵ埃利希，MD，首席执行官
    卡尔Birthistle，医学博士，副总裁兼全球法规事务
    阿兰CHEVALLIER，首席财务官
    伯纳德Fanget，副总裁工艺开发和制造
    丹尼尔·肯尼，首席商务官兼业务发展副总裁
    迪迪埃·谢勒博士，副总裁兼研发的小分子
    文森特·塞拉博士，副总裁兼研发病毒疫苗
    皮埃尔Vandepapelière医师，博士，首席医疗官和副总裁临床开发


董事局ABIVAX

    菲利普Pouletty，医学博士，董事长（执行合伙人 - 松露首都）
    欢乐阿蒙德森，百特生物科技的前总统，Covidien公司的董事会
    克劳德·贝特朗，执行副总裁ř易普森的研发
    让 - 雅克·贝特朗，安万特 - 巴斯德，皮埃尔·法布尔的总裁兼首席执行官前
    杰罗姆Gallot，威立雅Transdev和威立雅环境的前任CEO
    安托万·加索尔，财务总监松露资本
    基督教皮埃雷，工业法国前部长
    让 - 保罗·Prieels，前高级副总裁研发的葛兰素史克生物制品
    米格尔Sieler，前董事长兼首席执行官拜耳法，Neovacs首席执行官


ABIVAX科学顾问委员会

    吕克Teyton教授，医学博士，博士，免疫学，斯克里普斯研究所，拉霍亚，CA，USA的（主席）部
    黛安·哈珀教授医学博士，主席，家庭，部门和老年医学，路易斯维尔大学，肯塔基州，美国
    教授克里斯托夫·胡贝尔博士，前主席，血液科，肿瘤科，德国美因茨大学
    让 - 保罗·Prieels，博士，前副总统的研发，在葛兰素史克生物制品，比利时，董事会ABIVAX
    劳伦斯Stanberry教授，医学博士，博士，主席，儿科，哥伦比亚大学，纽约，美国科
    教授贾马尔 - 塔子，博士，分子遗传学系，法国蒙彼利埃大学
    教授马克A.温伯格博士，博士，主任麦吉尔大学艾滋病中心，加拿大蒙特利尔


关于ABIVAX

ABIVAX是一家总部位于巴黎的临床阶段生物制药公司，致力于成为全球领先的治疗性疫苗和抗病毒化合物的发现，开发和商业化对待一些世界上最重要的传染病。

该ABIVAX发展组合包括2个先导化合物是在临床研究阶段：ABX203，治疗性疫苗的候选人，可能是一种治疗慢性乙型肝炎和ABX464，防治艾滋病的一种新型小分子。更广泛的ABIVAX组合包括附加治疗性疫苗和抗病毒化合物，可能在未来的12-18个月内进入临床阶段。

ABIVAX利用技术平台，利用RNA - 蛋白质相互作用的干扰，B细胞和细胞毒性TH1细胞的扩增，产生专利突破疗法，旨在帮助患者明确的重要致病病毒，如HIV，HBV和HPV。

ABIVAX进行了研究和开发，埃夫里（法国）和蒙彼利埃（法国）。此外，ABIVAX受益于与古巴中心遗传工程和生物技术（古巴哈瓦那），不列颠哥伦比亚省癌症机构（加拿大温哥华），国家科学研究中心（法国蒙彼利埃），斯克里普斯研究所（拉霍亚长期的合作伙伴关系，CA，USA），芝加哥杨百翰大学大学（芝加哥，IL，USA），（普罗沃，UT，USA）和巴斯德研究所（法国巴黎）。 ABIVAX还打算寻求业务发展机会，以获取商业产品的许可协议，作为其整体战略的一部分。

欲了解更多信息，请访问公司网站：http://www.abivax.com

往来

ABIVA
教授哈特穆特·J·埃尔利希，CEO

媒体关系
哲基杰讯
阿里·莱文 - 露西Larguier（巴黎）
大卫Dible（伦敦）
[email protected]/大卫。 [email protected]
+33-1-53-32-84-71/+44-20-7282-2949

来源ABIVAX